Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 plus SBRT in unresectable or metastatic advanced solid tumors
ChiCTR2300071515Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in Nonhematologic neoplasms, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Objective response rate, Disease control rate and 1 more. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2300071515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071515.